Data from a Phase 1b dose-escalation study of PTC596 to treat patients with a variety of solid tumors are reported in our poster presented at the 2017 American Society of Clinical Oncology (ASCO) meeting, held in Chicago
ASCO 2017 poster: Phase 1b results of PTC596, a novel small molecule targeting cancer stem cells (CSCs) by reducing levels of BMI1 protein
GL-CORP-0207 | June 2021
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.